SciELO - Scientific Electronic Library Online

vol.34 número4Evolución de la definición del síndrome de insuficiencia respiratoria agudaCartílago de tiburón: una panacea oncológica más índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • No hay artículos similaresSimilares en SciELO


Medicina interna de México

versión impresa ISSN 0186-4866


MATTA-HERRERA, Gabriel Jaime; BALLESTAS-ALARCON, Luis Manuel  y  RAMIREZ-RINCON, Alex. GLP-1 agonists plus SGLT2 inhibitors. Additive cardioprotective effects?. Med. interna Méx. [online]. 2018, vol.34, n.4, pp.601-613. ISSN 0186-4866.

In South America, Colombia is secondly with number of diagnosed patients with diabetes mellitus (DM) and probably non-diagnostic patients. It has been calculated in Colombia 2 million people with diabetes mellitus, with a prevalence of 9.6% and it is the fifth position of causes of death and within the 10 causes that motivate the search for help. The new therapies with glucagon-like-1 receptors agonists (GLP-1 RAs) and SGLT2 inhibitors (SGLT2i) have been shown individually and through different mechanisms of action impact on the metabolic control and other variables such as blood pressure, lipid profile, weight, renal and cardiovascular protection. Type 2 diabetes mellitus treatment guides recommend for patients with dual therapy who continue HA1c out of goals, consider triple therapy if the patient has not achieved the goals after three months. A systematic search was made that included search engines such as Pubmed, Embase and Cochrane, resulting in 12 articles. More clinical studies should be done with the combination of GLP-1 RAs and SGLT2i in the context of patients with type 2 diabetes mellitus with poor metabolic control despite dual and triple therapies.

Palabras llave : Glucagon; Type 2 diabetes mellitus.

        · resumen en Español     · texto en Español     · Español ( pdf )